Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
Rom Leidner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill Hallin et al.
NATURE MEDICINE (2022)
Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming
Ashley Velez-Delgado et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Nasser Hosein et al.
NATURE CANCER (2022)
The vascular landscape of human cancer
Benjamin M. Kahn et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Adham S. Bear et al.
NATURE COMMUNICATIONS (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
Robert Vander Velde et al.
NATURE COMMUNICATIONS (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Nune Markosyan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
Giulia Biffi et al.
CANCER DISCOVERY (2019)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Andrew J. Rech et al.
CANCER RESEARCH (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Yaqing Zhang et al.
ELIFE (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Metastatic progression is associated with dynamic changes in the local microenvironment
Nicole M. Aiello et al.
NATURE COMMUNICATIONS (2016)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
Rafael Carretero et al.
NATURE IMMUNOLOGY (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Dominic E. Sanford et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
Lauren J. Bayne et al.
CANCER CELL (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Meredith A. Collins et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
Meredith A. Collins et al.
PLOS ONE (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)